Krystal Biotech, Inc. Stock price

Equities

KRYS

US5011471027

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-18 pm EDT 5-day change 1st Jan Change
168.5 USD -2.57% Intraday chart for Krystal Biotech, Inc. -1.09% +35.85%
Sales 2024 * 255M Sales 2025 * 416M Capitalization 4.77B
Net income 2024 * 47M Net income 2025 * 141M EV / Sales 2024 * 16.6 x
Net cash position 2024 * 535M Net cash position 2025 * 689M EV / Sales 2025 * 9.8 x
P/E ratio 2024 *
96.1 x
P/E ratio 2025 *
33.9 x
Employees 229
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.17%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.57%
1 week-1.93%
Current month+5.68%
1 month+48.39%
3 months+45.59%
6 months+40.24%
Current year+35.85%
More quotes
1 week
165.56
Extreme 165.56
181.42
1 month
107.50
Extreme 107.5
189.97
Current year
107.50
Extreme 107.5
189.97
1 year
72.18
Extreme 72.18
189.97
3 years
38.86
Extreme 38.8563
189.97
5 years
20.58
Extreme 20.58
189.97
10 years
8.03
Extreme 8.03
189.97
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 16-04-14
Founder 59 16-04-14
Chief Tech/Sci/R&D Officer - 22-06-30
Members of the board TitleAgeSince
Director/Board Member 58 16-10-31
Founder 59 16-04-14
Director/Board Member 69 17-05-31
More insiders
Date Price Change Volume
24-03-18 168.5 -2.57% 387,450
24-03-15 173 +0.66% 1,025,879
24-03-14 171.8 -4.19% 531,577
24-03-13 179.4 +0.22% 464,868
24-03-12 179 +5.02% 563,647

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Krystal Biotech, Inc. is a biotechnology company. The Company is focused on the development of redosable gene therapies for patients living with debilitating diseases. It has developed a gene delivery platform that enables off-the-shelf treatments for serious dermatology and respiratory diseases. Its platform consists of an engineered viral vector derived from the herpes simplex virus type 1 (HSV-1) that it has optimized for local and repeat gene transfer to epithelial cells. Its product candidates in various stages of clinical and preclinical development include Vyjuvek for dystrophic epidermolysis bullosa (Dystrophic EB), KB105 for TGM1-deficient autosomal recessive congenital ichthyosis (ARCI), KB104 for Netherton Syndrome, KB407 for Cystic Fibrosis (CF), and KB408 for Alpha-1 antitrypsin deficiency (AATD). Its KB301 is for aesthetic skin conditions. The Company's subsidiary, Jeune Aesthetics, Inc., which focuses on preclinical and clinical studies for aesthetic skin conditions.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
168.5 USD
Average target price
185.9 USD
Spread / Average Target
+10.31%
Consensus
  1. Stock
  2. Equities
  3. Stock Krystal Biotech, Inc. - Nasdaq